More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

receiving semaglutide (Wegovy®) for chronic weight management. After completing the efficacy dose-finding portion of the ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

With their lengthening laundry list of health benefits, drugs like Ozempic are showing promise for people who struggle with addiction.